APEC-1

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameAPEC-1

Drug Alias NameAPEC-1

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Recombinant polypeptide

Mechanisms of ActionB-lymphocyte antigen CD20 inhibitors

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesRevitope Oncology Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRevitope Oncology Inc

Active IndicationsN/A

Inactive IndicationsHematologic NeoplasmsLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A